9 results
Primary objective:Assesment of feasibility and toxicity of T cell depleted NMA Allo-SCT followed by lenalidomide or lenalidomide combined with bortezomib,and subsequent DLI; as treatment of relapsed multiple myeloma.Secondary objectives:To…
The objectives of this study are to compare the safety and efficacy of 2 annual cycles of intravenous (IV) alemtuzumab to 3-times weekly subcutaneous (SC) interferon beta 1a (Rebif*) in patients with active relapsing-remitting multiple sclerosis (…
The primary objective of this study is to determine if the binding of [11C]PK11195, as a measure of neuroinflammation, in schizophrenic patients is decreased after simvastatin treatment.
The objective is to study the feasibility of different PET tracers to detect vulnerable plaques in patients with a recent acute coronary syndrome and co-localize these inflammatory lesions with anatomical plaque features obtained with CT based…
The objective of this study is to assess the distribution of infusion associated reactions (IARs) by severity grade when Lemtrada is administered to RRMS patients who will be medicated according to specified algorithm designed to manage infusion…
To evaluate the long-term safety and efficacy of alemtuzumab, for patients already treated with this medicine in preceding clinical trials (CARE-MS I, CARE-MS II and CAMMS03409).
The objectives of this study are to examine: (1) the long-term safety and efficacy of alemtuzumab in multiple sclerosis (MS) patients who received alemtuzumab during prior Genzyme-sponsored studies including CAMMS223, CAMMS323, or CAMMS32400507 (…
The primary objective of this study is to evaluate whether there is an increased binding potential of the TSPO ligand [11C]PK11195, which is a marker for microglia activation in neuroinflammation, using PET in patients with CFS compared to healthy…
This is a medical-scientific research study. The purpose of the study is to investigate the effect of multiple doses of the study compound BIA 28-6156 on the pharmacokinetics of the drugs levodopa-carbidopa (Group 1) and levodopa-benserazide (Group…